HPMA copolymer platinates as novel antitumour agents: In vitro properties, pharmacokinetics and antitumour activity in vivo

European Journal of Cancer

Volumn 35, Issue 6, 1999, Pages 994-1002

  Gianasi, E ^a   Wasil, M ^a   Evagorou, E G ^a   Keddle, A ^a   Wilson, G ^b   Duncan, R ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b Glynn Wilson Group   (United States)

Author keywords

Cisplatin; Drug targeting; HPMA copolymers; Polymeric anticancer agent

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DIAMINE; FUNCTIONAL GROUP; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; PEPTIDE; PLATINUM; PLATINUM DERIVATIVE; POLYMER; TETRACHLOROPLATINATE POTASSIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CYTOTOXICITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG UPTAKE; IN VITRO STUDY; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; MALE; MELANOMA; METHACRYLATES; MICE; PLATINUM; TUMOR CELLS, CULTURED;

EID: 0033152928     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00030-1     Document Type: Article

References (46)

1. Rozencweig M., Von Hoff D.D., Slovik M. Cisdiamminedichloroplatinum(II), a new anticancer drug. Ann. Intern. Med. 86:1977;803-812.
2. Prestayko A.W., D'Aoust J.C., Issell B.F., Crooke S.T. Cisplatin cisdiamminedichloroplatinum(II). Cancer Treat. Rev. 6:1979;17-39.
3. Rosenberg B., Van-Camp L., Trosko J.F., Mansour V.H. Platinum compounds: a new class of potent antitumour agents. Nature. 222:1967;385-396.
4. Chabner BA. Cancer: Principles and Practice of Oncology. Philadelphia, JB Lippincott Co, 1990.
5. Van der Veer J.L., Reedijk J. Investigating antitumour drug mechanisms. Chem. Br. 24:1988;775-780.
6. Gordon M., Hollander S. Review of platinum anticancer compounds. J. Med. 24:1993;209-265.
7. Kelland L.R. New platinum antitumor complexes. Crit. Rev. Oncol. Hematol. 15:1993;191-219.
8. Weiss R.B., Christian M.C. New cisplatin analogues in development: a review. Drugs. 46:1993;360-377.
9. Christian M.C. The current status of new platinum analogues. Semin. Oncol. 9:1992;720-733.
10. Chabner BA, Collins JM. Cancer Chemotherapy: Principles and Practice. Philadelphia, JB Lippincott Co, 1983.
11. Kleinberg J. Inorganic Synthesis. New York, McGraw-Hill, 1963.
12. Groth S., Nielson H., Sorenson J.B., Christensen A.B., Pedersen A.G., Orrth M. Acute and long term nephrotoxicity of cisplatin in man. Cancer Chemother. Pharmacol. 17:1986;191-196.
13. Eastmen A, Schulte N, Sheibani N, Sorenson CN. Mechanisms of resistance to platinum drugs. In Nicolini M, ed. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. Boston, Martinus Nijhoff, 1988, 178-217.
14. Shen D.W., Akiyama S.I., Schoenlein P., Pastan I., Gottesman M. Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br. J. Cancer. 71:1995;676-683.
15. Siddik Z.H., Thai G., Yoshida M., Zhang Y.P., Khokhar A.R. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo. Anti-cancer Drug Design. 9:1994;495-509.
16. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumour agent SMANCS. Cancer Res. 46:1986;6387-6392.
17. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anti Cancer Drugs. 3:1992;175-210.
18. Duncan R., Dimitrijevic S., Evagorou E.G. The role of polymer conjugates in the diagnosis and treatment of cancer. S T P Pharmac. Sci. 6:1996;237-263.
19. Vasey PA, Duncan R, Twelves C, Kaye SB, Strolin-Benedetti M, Cassidy J. Clinical and pharmacokinetic phase I study of PK1 (HPMA co-polymer doxorubicin). 9th NCI-EORTC Symp on New Drugs in Cancer Therapy 1996, 338, 97.
20. Cassidy J., Duncan R., Morrison G.J.et al. Activity of N-(2- hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumour model. Biochem. Pharmacol. 38:1989;875-879.
21. Seymour L.W., Ulbrich K., Steyger P.S.et al. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer. 70:1994;636-641.
22. Duncan R., Cable H.C., Lloyd J.B., Rejmanova P., Kopecek J. Degradation of side-chains of N-(2-hydroxypropyl)methacrylamide copolymers by lysosomal thiol-proteinases. Bioscience Reps. 2:1983;1041-1046.
23. Foekens J.A., Kos J., Peters H.A.et al. Prognostic significance of cathepsins B and L in primary human breast cancer. J. Clin. Oncol. 16:1998;1013-1021.
24. Rihova B., Bilej M., Vetvicka V.et al. Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin-immunogenicity and effect on hematopoietic stem cells in bone-marrow in vivo and mouse splenocytes and human peripheral blood lymphocytes in vitro. Biomaterials. 10:1989;335-342.
25. Yeung T.K., Hopewell J.W., Simmonds R.H.et al. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: an experimental study in the rat. Cancer Chem. Pharmacol. 29:1991;105-111.
26. Schecter B., Pauzner R., Arnon R., Wilcheck M. Cisplatin(II) complexes of carboxymethyl dextran as potential antitumour agents. (II). In vitro, and in vivo activity. Cancer Biochem. Biophys. 8:1986;289-298.
27. Schecter B., Wicheck M., Arnon R. Increased therapeutic efficacy of cisplatin complexes of poly-L-glutamic acid against murine carcinoma. Int. J. Cancer. 39:1987;409-413.
28. Neuse E.W., Caldwell G., Perlwitz A.G. Cis-diaminedichloroplatinum(II) complexes reversibly bound to water-soluble polyaspartamide carriers for chemotherapeutic applications. 2. Platinum coordination to ethylenediamine ligands attached to poly(ethylene oxide) grafted carrier polymers. J. Inorg. Organomet. Polymers. 5:1995;195-207.
29. Schechter B., Neumann A., Wilchek M., Arnon R. Soluble polymers as carriers of cis-platinum. J. Contr. Rel. 10:1989;75-87.
30. Ohya Y., Masunaga T., Baba T., Ouchi T. Synthesis and cytotoxic activity of dextran-immobilizing platinum (II) complex through chelate-type coordination bond. J M S Pure Appl. Chem. A33:1996;1005-1016.
31. Imai T., Fujii K., Shiraishi S., Otagiri M. Alteration of pharmacokinetics and nephrotoxicity of cisplatin by alginates. J. Pharm. Science. 86:1997;244-247.
32. Yokoyama M., Okano T., Sakurai Y., Suwa S., Kataoka K. Introduction of cisplatin into polymeric micelle. J. Contr. Rel. 39:1996;351-356.
33. Duncan R, Evagorou EG, Buckley RG, Gianasi E, US Patent Appl. 09/060,4555 (1998).
34. Sgouras D., Duncan R. Methods for the evaluation of biocompatibility of soluble synthetic polymers which have potential biomedical use: 1 - Use of tetrazolium-based calorimetric assay (MTT) as a preliminary screen for evaluation in-vitro cytotoxicity. J. Mater. Sci. Mater. Med. 1:1990;67-68.
35. Schechter B., Pauzner R., Arnon R., Wilchek M. Cis-platinum(II) complexes of carboxymethyl-dextran as potential antitumour agents I. Preparation and characterization. Cancer Biochem. Biophys. 8:1986;277-287.
36. Connors T.A. Is there a future for cancer chemotherapy? Ann. Oncol. 7:1996;445-452.
37. Seymour L.W., Ulbrich K., Strohalm J., Kopecek J., Duncan R. The pharmacokinetics of polymer-bound adriamycin. Biochem. Pharm. 39:1990;1125-1131.
38. Vasey P.A., Kaye S.B., Morrison R.et al. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin Cancer Res. 5:1999;83-94.
39. Kerr DJ, Seymour LW, Boivin C, et al. Phase I clinical trial of HPMA copolymers bearing doxorubicin and galactosamine. Proceedings of the 3rd Int'l Symp on Polymer Therapeutics (London, U.K.) 1998. 23.
40. Ten Bokkel Huniunk WW, Meerum Terwogt J, Dubbelman R, et al. Phase I study of PNU 166945, a polymer formulated paclitaxel. Proceedings of the 3rd Int'l Symp on Polymer Therapeutics (London, U.K.) 1998, 12.
41. Duncan R., Evagorou E.G., Buckley R.G., Gianasi E., Wasil M., Wilson G. Comparative evaluation of novel polymer platinates. 1. Synthesis, characterisation and in vitro properties. Proceedings of the Int'l. Symp. Control Rel. Bioact. Mater. 24:1997;775-776.
42. Duncan R., Hume I.C., Kopeckova P., Ulbrich K., Strohalm J., Kopecek J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers, 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo. J. Contr. Rel. 10:1989;51-63.
43. Duncan R., Hume I.C., Yardley H.J.et al. Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N-(2-hydroxypropyl)methacrylamide copolymers. J. Contr. Rel. 16:1991;121-136.
44. Loh S.Y., Mistry P., Kelland L.R., Abel G., Harrap K.R. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine famine complexes. Br. J. Cancer. 66:1992;1109-1115.
45. Richon V.M., Schulte N., Eastman A. Multiple mechanisms of resistance to cis-diammine dichloro platinum (II) in murine leukaemia L1210 cells. Cancer Res. 47:1987;2056-2061.
46. Evagorou EG, Buckley RG, Gianasi E, et al. Synthesis and characterisation of HPMA copolymer conjugates containing amino, carboxylato and dicarboxylato bound platinates. Proceedings of the 3rd Int'l Symp on Polymer Therapeutics: Laboratory to Clinic, 7-9 Jan, London 1998, p. 71.